2016-03-09T00:00:00.000-05:00
lung cancer patients,-0.300112
NSCLC patients,0.414776
net proceeds,0.334528
oncology drug development,0.495306
period,-0.364516
expansion clinical trial,0.225176
dose expansion,0.225176
potential breakthrough cancer,-0.247462
specific driver alterations,0.506379
drug candidates,-0.347012
clinical development strategies,0.506379
significant risks,-0.512252
immuno-oncology combination therapies,-0.415793
clinical trial,0.319976
clinical development,0.506379
Guardant Health,0.414776
Charles M. Baum,-0.218469
cancer therapies,-0.247462
news release,-0.411788
oncology precision medicine,0.819172
net loss,-0.471846
forward-looking statements,-0.411788
Mirati team,-0.247462
quarter,-0.346816
